Skip to main content
Raajit Rampal, MD, Oncology, New York, NY

RaajitRampalMD

Oncology New York, NY

Physician

Overview of Dr. Rampal

Dr. Raajit Rampal is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 10 years. He is one of 493 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2007 - 2009
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 2007

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2009 - 2026
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • NH State Medical License
    NH State Medical License 2024 - 2024
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • ME State Medical License
    ME State Medical License 2020 - 2021
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy of MEK Inhibition in Patients with Histiocytic Neoplasms  
    Robert J Young, Mario Lacouture, Neal Rosen, David M Hyman, Raajit Rampal, Gary A Ulaner, Benjamin H Durham, Lynn A Brody, Nature
  • Genetic and Epigenetic Evolution as a Contributor to WT1-Mutant Leukemogenesis  
    Raajit Rampal, Ross L Levine, Benjamin H Durham, Blood
  • Jak2V617F and Dnmt3a Loss Cooperate to Induce Myelofibrosis Through Activated Enhancer-Driven Inflammation  
    Raajit Rampal, MD, Blood

Abstracts/Posters

  • Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms
    Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells
    Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin
    Raajit K. Rampal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Myelofibrosis: Considering TP53 and Post-MPN AML
    Myelofibrosis: Considering TP53 and Post-MPN AMLSeptember 5th, 2024
  • Demystifying the Lab: Cytogenetics
    Demystifying the Lab: CytogeneticsJuly 1st, 2021
  • Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
    Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH MeetingDecember 6th, 2020
  • Join now to see all